Atossa Therapeutics Inc (ATOS)

$0.79 +0.02 (2.18%)
Market Cap 101.79M
Revenue (ttm) 0.00
Net Income (ttm) -25.50M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 558,800
Avg Vol 1,206,878
Day's Range N/A - N/A
Shares Out 129.17M
Stochastic %K 79%
Beta 1.10
Analysts Strong Sell
Price Target $5.62

Company Profile

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa...

Industry: Biotechnology
Sector: Healthcare
Phone: 206-588-0256
Fax: 206 902 9658
Address:
107 Spring Street, Seattle, United States
JDAAT
JDAAT Sep. 8 at 3:42 AM
$ATOS
0 · Reply
MrLowellRedlingsFarquhar
MrLowellRedlingsFarquhar Sep. 7 at 8:15 PM
$ATOS
0 · Reply
MrLowellRedlingsFarquhar
MrLowellRedlingsFarquhar Sep. 7 at 8:14 PM
0 · Reply
JDAAT
JDAAT Sep. 5 at 10:55 PM
$ATOS
0 · Reply
nepepe
nepepe Sep. 5 at 10:10 PM
$ATOS soon not so boring
0 · Reply
iBoughtTheWrongTicker
iBoughtTheWrongTicker Sep. 5 at 8:47 PM
$ATOS so boring here
0 · Reply
JDAAT
JDAAT Sep. 5 at 5:31 PM
$ATOS
0 · Reply
traylindo
traylindo Sep. 5 at 5:09 PM
$ATOS what color is that
1 · Reply
AdamantiumBull
AdamantiumBull Sep. 5 at 4:49 PM
$ATOS 2.5 cents up! OMG.
2 · Reply
JBS_84
JBS_84 Sep. 5 at 4:31 PM
$ATOS
0 · Reply
Latest News on ATOS
Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference

Aug 28, 2025, 8:30 AM EDT - 10 days ago

Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference

Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer

Aug 20, 2025, 8:30 AM EDT - 18 days ago

Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer

Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update

Aug 12, 2025, 8:30 AM EDT - 26 days ago

Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update

Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer

Jul 29, 2025, 7:45 AM EDT - 5 weeks ago

Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference

Jun 2, 2025, 8:45 AM EDT - 3 months ago

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22

May 20, 2025, 9:00 AM EDT - 3 months ago

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22

Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen

May 14, 2025, 8:15 AM EDT - 4 months ago

Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen

Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

May 13, 2025, 8:00 AM EDT - 4 months ago

Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

Apr 30, 2025, 8:45 AM EDT - 4 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

Apr 29, 2025, 8:45 AM EDT - 4 months ago

Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

Apr 22, 2025, 8:45 AM EDT - 4 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

Apr 10, 2025, 8:00 AM EDT - 5 months ago

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 10:05 AM EDT - 5 months ago

Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Mar 25, 2025, 8:00 AM EDT - 5 months ago

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Mar 20, 2025, 9:13 AM EDT - 6 months ago

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

Mar 11, 2025, 8:15 AM EDT - 6 months ago

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

Feb 5, 2025, 8:00 AM EST - 7 months ago

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No.

Jan 30, 2025, 8:17 AM EST - 7 months ago

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No.

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

Jan 23, 2025, 8:15 AM EST - 8 months ago

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

Dec 12, 2024, 8:15 AM EST - 9 months ago

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

Dec 11, 2024, 8:15 AM EST - 9 months ago

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

Dec 10, 2024, 9:05 AM EST - 9 months ago

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research

Dec 9, 2024, 8:15 AM EST - 9 months ago

Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

Nov 21, 2024, 8:30 AM EST - 10 months ago

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

Nov 20, 2024, 8:30 AM EST - 10 months ago

Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 12, 2024, 8:30 AM EST - 10 months ago

Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

Nov 5, 2024, 8:30 AM EST - 10 months ago

Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:

Nov 4, 2024, 6:30 AM EST - 10 months ago

Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:

Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

Oct 31, 2024, 8:15 AM EDT - 11 months ago

Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer

Oct 21, 2024, 8:30 AM EDT - 11 months ago

Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer

Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit

Oct 14, 2024, 5:08 PM EDT - 11 months ago

Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit

Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum

Oct 1, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum

Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer

Sep 10, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer

Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Atossa Therapeutics Granted Additional Patent Protection for Endoxifen

Aug 28, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Granted Additional Patent Protection for Endoxifen

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

Aug 21, 2024, 11:30 AM EDT - 1 year ago

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

Aug 20, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 12, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

Jul 22, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer

Jul 2, 2024, 4:15 PM EDT - 1 year ago

Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

Jun 28, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

Atossa Set to Join Russell 3000® Index Effective June 28, 2024

Jun 17, 2024, 8:30 AM EDT - 1 year ago

Atossa Set to Join Russell 3000® Index Effective June 28, 2024

Atossa to Present at the Sidoti Small-Cap Investor Conference

Jun 5, 2024, 8:30 AM EDT - 1 year ago

Atossa to Present at the Sidoti Small-Cap Investor Conference

Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

May 28, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial

May 15, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial

Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024, 8:50 AM EDT - 1 year ago

Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines

May 7, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines

Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen

Apr 29, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen

Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

Apr 15, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

Apr 11, 2024, 8:30 AM EDT - 1 year ago

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

JDAAT
JDAAT Sep. 8 at 3:42 AM
$ATOS
0 · Reply
MrLowellRedlingsFarquhar
MrLowellRedlingsFarquhar Sep. 7 at 8:15 PM
$ATOS
0 · Reply
MrLowellRedlingsFarquhar
MrLowellRedlingsFarquhar Sep. 7 at 8:14 PM
0 · Reply
JDAAT
JDAAT Sep. 5 at 10:55 PM
$ATOS
0 · Reply
nepepe
nepepe Sep. 5 at 10:10 PM
$ATOS soon not so boring
0 · Reply
iBoughtTheWrongTicker
iBoughtTheWrongTicker Sep. 5 at 8:47 PM
$ATOS so boring here
0 · Reply
JDAAT
JDAAT Sep. 5 at 5:31 PM
$ATOS
0 · Reply
traylindo
traylindo Sep. 5 at 5:09 PM
$ATOS what color is that
1 · Reply
AdamantiumBull
AdamantiumBull Sep. 5 at 4:49 PM
$ATOS 2.5 cents up! OMG.
2 · Reply
JBS_84
JBS_84 Sep. 5 at 4:31 PM
$ATOS
0 · Reply
zerotrust07
zerotrust07 Sep. 5 at 4:21 PM
$ATOS anyone know if this may go back down to the 50 cent area? I need to average down more to jump ship. Getting tired of waiting for some big pay off here.
4 · Reply
_level_m_
_level_m_ Sep. 5 at 3:37 PM
$ATOS
1 · Reply
Warrens__Buffet_
Warrens__Buffet_ Sep. 5 at 2:58 PM
$ATOS he may have posted about Covid but haven’t checked
0 · Reply
Michaeljin_101
Michaeljin_101 Sep. 5 at 2:25 PM
$ATOS did the doc just posted something on X? I’m about to board a flight.
2 · Reply
Joe_088
Joe_088 Sep. 5 at 2:25 PM
$ATOS $EKSO
0 · Reply
DCalcote
DCalcote Sep. 5 at 2:10 PM
$ATOS
0 · Reply
dcajic2
dcajic2 Sep. 5 at 2:03 PM
$ATOS Can this comoany really survive?? So many bulls have. Even saying bullish since Covid and the company still can’t get their stock above $1
0 · Reply
Warrens__Buffet_
Warrens__Buffet_ Sep. 5 at 1:39 PM
$ATOS needs to go below .75 today no reason this should be holding here
1 · Reply
Knowspicker3
Knowspicker3 Sep. 5 at 1:37 PM
$ATOS
0 · Reply
Kittyc803
Kittyc803 Sep. 5 at 1:35 PM
$ATOS Morning 🙌 people . Getting sick of these .70s . Something needs to break . GLTA 🍀
0 · Reply
FLNY
FLNY Sep. 5 at 1:25 PM
$ATOS
0 · Reply
Bunster
Bunster Sep. 5 at 1:24 PM
$ATOS or in the CASE OF ATOS KEEP SELLING UNTIL IT MAKES SENSE TO BUY!!!!!!!!!!!!!!
0 · Reply